TGen to Conduct Phase I Study of Prolexys Anti-Cancer Drug | GenomeWeb
Prolexys Pharmaceuticals yesterday announced the start of its first human trials of PRLX 93936, a potential anti-cancer compound.
 
Among the study centers performing the phase I studies of this erastin analog is TGen Clinical Research. At TGen and the other study sites, the safety, efficacy, and pharmocodynamic properties of PRLX 93936 will be evaluated in patients with advanced solid tumors.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic analysis of pollutant-tolerant fish, and more.

Researchers have found a rare carbapenem resistance gene on a US pig farm, NBC News reports.

New York officials are considering the use of a familial DNA search to get a lead on a suspect in the strangulation death of a runner.

NIH Director Francis Collins has selected a retired Army major general and cardiologist for the CEO spot at the agency's embattled Clinical Center.